C
Concepcion F. Estivariz
Researcher at Centers for Disease Control and Prevention
Publications - 36
Citations - 1263
Concepcion F. Estivariz is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Inactivated Poliovirus Vaccine & Poliomyelitis. The author has an hindex of 17, co-authored 34 publications receiving 1121 citations.
Papers
More filters
Journal ArticleDOI
Vaccine-Associated Paralytic Poliomyelitis: A Review of the Epidemiology and Estimation of the Global Burden
TL;DR: Because many high-income countries have replaced OPV with inactivated poliovirus vaccine, the VAPP burden is concentrated in lower- Income countries, and the planned universal introduction of inactivatedPoliov virus vaccine is likely to substantially decrease the global VAPPurden by 80%-90%.
Journal ArticleDOI
Outbreak of Mycobacterium abscessus wound infections among "lipotourists" from the United States who underwent abdominoplasty in the Dominican Republic.
E. Yoko Furuya,Armando Paez,Arjun Srinivasan,Robert C. Cooksey,Michael Augenbraun,Miriam J. Baron,Karen Brudney,Phyllis Della-Latta,Concepcion F. Estivariz,Staci A. Fischer,Mary Flood,Pamela Kellner,Carmen Roman,Mitchell A. Yakrus,Don Weiss,Eric V. Granowitz +15 more
TL;DR: This case series of M. abscessus infection in US "lipotourists" highlights the risks of traveling abroad for surgery and the potential role of the Internet in identifying and investigating outbreaks.
Journal ArticleDOI
Efficacy of inactivated poliovirus vaccine in India
Hamid Jafari,Jagadish M. Deshpande,Roland W. Sutter,Sunil Bahl,Harish Verma,Mohammad Ahmad,Abhishek Kunwar,Rakesh Vishwakarma,Ashutosh Agarwal,Shilpi Jain,Concepcion F. Estivariz,Raman Sethi,Natalie A. Molodecky,Nicholas C. Grassly,Mark A. Pallansch,Arani Chatterjee,R. Bruce Aylward +16 more
TL;DR: Controversy over vaccine choice for polio eradication can be reconciled by effective combined use of IPV and Sabin together, and IPV in OPV-vaccinated individuals boosts intestinal mucosal immunity.
Journal ArticleDOI
Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
Abhijeet Anand,K. Zaman,Concepcion F. Estivariz,Mohammad Yunus,Howard E. Gary,William C. Weldon,Tajul I Bari,M. Steven Oberste,Steven G. F. Wassilak,Stephen P. Luby,James D. Heffelfinger,Mark A. Pallansch +11 more
TL;DR: If IPV induced priming at age 6 weeks is similar to that at age 14 weeks, IPV could be administered at a younger age and possibly with a higher coverage, and inferior immunogenicity of one-fifth f-IPV compared with IPV is demonstrated.
Journal ArticleDOI
Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6–9 months in Moradabad, India: a community-based, randomised controlled trial
Concepcion F. Estivariz,Hamid Jafari,Roland W. Sutter,T. Jacob John,Vibhor Jain,Ashutosh Agarwal,Harish Verma,Mark A. Pallansch,Ajit P Singh,Sherine Guirguis,Jitendra Awale,Anthony H. Burton,Sunil Bahl,Arani Chatterjee,R. Bruce Aylward +14 more
TL;DR: Assessing the current immunity profile after routine doses of trivalent oral poliovirus vaccine (OPV) and numerous supplemental doses of type-1 monovalent OPV (mOPV1), and compared the effect of five vaccine formulations and dosages on residual immunity gaps found almost total seroprevalence against poliov virus type 1, which is consistent with recent absence of poliomyelitis cases.